Targeting the ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC

Sunitinib has been used as the main therapy to treat the metastatic clear cell renal cell carcinoma (ccRCC) as it could function via suppressing the tumor growth and angiogenesis. Yet most ccRCC tumors may still regrow due to the development of sunitinib-resistance, and detailed mechanisms remain to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Death Dis
Autors principals: Gu, Junfei, Zhang, Yong, Han, Zhenwei, Gao, Lei, Cui, Jinfeng, Sun, Yin, Niu, Yuanjie, You, Bosen, Huang, Chi-Ping, Chang, Chawnshang, Wang, Xiaolu, Yeh, Shuyuan
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7224303/
https://ncbi.nlm.nih.gov/pubmed/32409702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2486-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars